Dergiler / Balkan Medical Journal / 2016 / Cilt: 33 - Sayı: 1

The Relationship between Telomerase Activity and Clinicopathological Parameters in Colorectal Cancer: A Meta-Analysis

Sayfa
64–71
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

TA can play a useful part in the prognosis and treatment of CRC patients, but further studies are required to confirm this

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background:Recently, accumulated research has found that the expression of telomerase activity (TA) was associated with colorectal cancer (CRC) advance-ment, whereas the TA prognostic effect in CRC patients is still controversial.
📊
Temel Bulgular & Veri:Aims: To investigate relationships between TA and CRC clinicopathological parameters.Study Design: Meta-analysis study.Methods: We searched published studies in databases, such as EMBASE, the Cochrane Library, PubMed, and Ovid databases (last search updated to October 2014) by meeting specified search criteria.
💡
Sonuç & Katkı:TA can play a useful part in the prognosis and treatment of CRC patients, but further studies are required to confirm this
🔬Tür:Araştırma Makalesi
📍Kapsam:2014 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background:Recently, accumulated research has found that the expression of telomerase activity (TA) was associated with colorectal cancer (CRC) advance-ment, whereas the TA prognostic effect in CRC patients is still controversial. Aims: To investigate relationships between TA and CRC clinicopathological parameters.Study Design: Meta-analysis study.Methods: We searched published studies in databases, such as EMBASE, the Cochrane Library, PubMed, and Ovid databases (last search updated to October 2014) by meeting specified search criteria. The quality of the included studies was usually evaluated and a meta-analysis was implemented by Stata 12.0 software. We used an odds ratio (OR) with a 95% confidence interval (CI) to evaluate relationship strengths between TA and CRC clinicopathological parameters.Results: In total, 11 studies (715 patients) were in-cluded to assess the relation between TA and metas-tasis-related parameters in CRC patients. The results indicate that a senior TA expression was connected with the existence of lymph node metastasis (180 pa-tients; OR=2.85, 95% CI=1.40-5.81, p=0.004), and tu-mor site (522 patients; OR=2.93, 95% CI=1.29-6.67, p=0.010). However, a senior TA expression was not connected with tumor size (137 patients; OR=1.57, 95% CI=0.71-3.47, p=0.267), histological differen-tiation (570 patients; OR=1.28, 95% CI=0.78-2.09, p=0.332), depth of invasion (57 patients; OR=3.76, 95% CI=0.61-23.04, p=0.152), distant metastasis (123 patients; OR=1.76, 95% CI=0.54-5.74, p=0.346), and clinical stage of the cancer (543 patients; OR=1.59, 95% CI=0.74-3.38, p=0.232).Conclusion: This meta-analysis suggests that a positive TA was correlated with lymph node metastasis progres-sion and tumor site of the CRC but did not correlate with other important clinicopathological parameters. TA can play a useful part in the prognosis and treatment of CRC patients, but further studies are required to confirm this

🔖

Bu Makaleye Atıf Yap

QIU, H., XIE, X., GE, L., LAI, H., TANG, F., QIN, Y. (2022). The Relationship between Telomerase Activity and Clinicopathological Parameters in Colorectal Cancer: A Meta-Analysis. Balkan Medical Journal, Cilt: 33 - Sayı: 1, 64–71. https://ajindex.com/articles/461264

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
  2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J N Cancer Inst 2004;96:1420-5.
  3. Hegde MV, Mali AV, Chandorkar SS. What is a cancer cell? Why does it metastasize? Asian Pac J Cancer Prev 2013;14:3987-9.
  4. Podlevsky JD, Chen JJ. It all comes together at the ends: telom- erase structure, function, and biogenesis. Mutat Res 2012;730:3- 11. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
  5. Cukusic A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res 2008;122:263-72.
  6. Chen CH, Chen RJ. Prevalence of telomerase activity in human cancer. J Formos Med Assoc 2011;110:275-89.
  7. Valls Bautista C, Pinol Felis C, Rene Espinet JM, Buenestado Garcia J, Vinas Salas J. Telomerase activity and telomere length in the colorectal polyp-carcinoma sequence. Rev Esp Enferm Dig 2009;101:179-86.
  8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epi- demiology: a proposal for reporting. Meta-analysis Of Obser- vational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
  9. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001;269:1-12.
  10. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999;18:1561-7.
  11. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327:557-60.
  12. Begg CB, Mazumdar M. Operating characteristics of a rank cor- relation test for publication bias. Biometrics 1994;50:1088-101.
  13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta- analysis detected by a simple, graphical test. BMJ 1997;315:629- 34. Brown T, Aldous W, Lance R, Blaser J, Baker T, Williard W. The association between telomerase, p53, and clinical staging in colorectal cancer. Am J Surg 1998;175:364-6.
  14. Okayasu I, Mitomi H, Yamashita K, Mikami T, Fujiwara M,